Lilly, Gilead, Amgen Started at Outperform by Bernstein
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Jefferies Sticks to Its Buy Rating for Gilead Sciences (GILD)
How Brookfield Infrastructure, Invitation Homes And Gilead Sciences Can Put Cash In Your Pocket
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
Unusual Options Activity: HES, TSLA and Others Attract Market Bets, HES V/OI Ratio Reaches 103.1
Morgan Stanley Adjusts Price Target on Gilead Sciences to $84 From $79
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
Morgan Stanley Remains a Hold on Gilead Sciences (GILD)
Is Gilead Sciences, Inc. (NASDAQ:GILD) The Most Popular Stock Among Mutual Funds According To Goldman Sachs?
Wells Fargo Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $100
Morgan Stanley raised gilead sciences target price to $100.
JPMorgan: Raises gilead sciences' target price from $95 to $100, maintains a "shareholding" rating.
Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...
Gilead Sciences Is Maintained at Overweight by JP Morgan
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Raymond James Adjusts Gilead Sciences Price Target to $95 From $94
Gilead To Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline And HIV Leadership At IDWeek 2024
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024